SOUL study - oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes
The SOUL study (n=9,650)
- found semaglutide reduced the risk of major adverse CV events vs placebo in people with type 2 diabetes and atherosclerotic CV disease and/or chronic kidney disease (3.1 vs 3.7 events per 100 person-years, respectively; HR 0.86; 95% CI 0.77 to 0.96; P=0.006)
- was a double-blind, placebo-controlled, event-driven, superiority trial
- randomly assigned participants who were 50 years of age or older, had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular disease, chronic kidney disease, or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care
- primary outcome was major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), assessed in a time-to-first-event analysis
Reference:
- McGuire DK et al; for the SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. NJEM March 29, 2025
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.